Published in Psychopharmacology (Berl) on July 02, 2005
Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev (2009) 5.64
It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol (2007) 2.85
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochem Pharmacol (2007) 1.49
Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology (2010) 1.37
Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav Pharmacol (2008) 1.23
Analysis of detailed phenotype profiles reveals CHRNA5-CHRNA3-CHRNB4 gene cluster association with several nicotine dependence traits. Nicotine Tob Res (2012) 1.22
Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. J Pharmacol Exp Ther (2011) 1.15
Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res (2008) 1.14
The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog Neurobiol (2010) 1.09
Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol (2009) 1.09
Nicotine and hippocampus-dependent learning: implications for addiction. Mol Neurobiol (2006) 1.09
Long-term effects of chronic nicotine exposure on brain nicotinic receptors. Proc Natl Acad Sci U S A (2007) 1.08
High affinity binding of epibatidine to serotonin type 3 receptors. J Biol Chem (2007) 0.93
Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet (2012) 0.92
bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol (2011) 0.91
Chrna4 A529 knock-in mice exhibit altered nicotine sensitivity. Pharmacogenet Genomics (2010) 0.89
Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol (2010) 0.89
The necessity of α4* nicotinic receptors in nicotine-driven behaviors: dissociation between reinforcing and motor effects of nicotine. Neuropsychopharmacology (2011) 0.89
Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo. Nicotine Tob Res (2012) 0.86
Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice. ISRN Pharmacol (2012) 0.83
Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol (2014) 0.83
From smoking to cancers: novel targets to neuronal nicotinic acetylcholine receptors. J Oncol (2011) 0.82
Mice expressing the ADNFLE valine 287 leucine mutation of the Β2 nicotinic acetylcholine receptor subunit display increased sensitivity to acute nicotine administration and altered presynaptic nicotinic receptor function. Pharmacol Biochem Behav (2012) 0.80
Nicotinic acetylcholine receptor expression in the hippocampus of 27 mouse strains reveals novel inhibitory circuitry. Hippocampus (2008) 0.80
In vivo effects of 3-iodocytisine: pharmacological and genetic analysis of hypothermia and evaluation of chronic treatment on nicotinic binding sites. Neuropharmacology (2009) 0.80
Nicotine-induced impulsive action: sensitization and attenuation by mecamylamine. Behav Pharmacol (2011) 0.80
Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehav Rev (2015) 0.78
Nicotine signaling and progression of chronic kidney disease in smokers. Biochem Pharmacol (2013) 0.78
Chronic treatment with varenicline changes expression of four nAChR binding sites in mice. Neuropharmacology (2015) 0.78
Differential expression of the beta4 neuronal nicotinic receptor subunit affects tolerance development and nicotinic binding sites following chronic nicotine treatment. Pharmacol Biochem Behav (2015) 0.77
Chronic nicotine pretreatment is sufficient to upregulate α4* nicotinic receptors and increase oral nicotine self-administration in mice. BMC Neurosci (2014) 0.77
Mouse models for studying genetic influences on factors determining smoking cessation success in humans. Ann N Y Acad Sci (2012) 0.77
Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies. J Clin Pharm Ther (2014) 0.76
Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 6.27
Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature (1995) 3.28
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol (1992) 3.20
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev (1999) 2.76
Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem (1988) 2.24
Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci (1998) 2.18
Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature (1999) 2.13
Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. J Neurosci (1999) 2.12
Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci (2002) 2.05
Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther (1983) 2.03
Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. J Neurosci (2004) 1.99
Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther (1997) 1.98
Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science (1983) 1.78
Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem (2002) 1.75
Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther (1999) 1.73
Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci (2000) 1.70
Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit. J Pharmacol Exp Ther (1999) 1.61
Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci (1988) 1.60
The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci (1990) 1.53
Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology (Berl) (1999) 1.51
Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem (1998) 1.45
Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol (1994) 1.44
Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J Pharmacol Exp Ther (2003) 1.35
Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. J Pharmacol Exp Ther (1998) 1.32
Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity. Mol Pharmacol (1998) 1.31
Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine. Br J Pharmacol (2000) 1.31
Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther (1997) 1.29
Subsets of acetylcholine-stimulated 86Rb+ efflux and [125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology (2004) 1.23
Genetic influences on nicotine responses. Pharmacol Biochem Behav (1989) 1.22
An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J Pharmacol Exp Ther (1991) 1.19
Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. Eur J Pharmacol (2002) 1.16
Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. Nicotine Tob Res (2004) 1.16
An extracellular protein microdomain controls up-regulation of neuronal nicotinic acetylcholine receptors by nicotine. J Biol Chem (2004) 1.15
Acute and chronic tolerance to nicotine measured by activity in rats. Psychopharmacologia (1973) 1.13
Chronic tolerance to nicotine in humans and its relationship to tobacco dependence. Nicotine Tob Res (2002) 1.07
Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J Neurochem (1997) 1.07
Genotype influences the development of tolerance to nicotine in the mouse. J Pharmacol Exp Ther (1991) 1.02
Techniques for the chronic cannulation of the jugular vein in mice. Pharmacol Biochem Behav (1979) 1.00
[3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J Pharmacol Exp Ther (1995) 1.00
Nicotine produces selective degeneration in the medial habenula and fasciculus retroflexus. Brain Res (2001) 0.98
Nicotinic-agonist stimulated (86)Rb(+) efflux and [(3)H]epibatidine binding of mice differing in beta2 genotype. Neuropharmacology (2000) 0.94
Chronic nicotine administration does not increase nicotinic receptors labeled by [125I]epibatidine in adrenal gland, superior cervical ganglia, pineal or retina. J Neurochem (2003) 0.94
Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.94
A test battery for measuring nicotine effects in mice. Pharmacol Biochem Behav (1985) 0.87
Genetic influences on acute responses to nicotine and nicotine tolerance in the mouse. Pharmacol Biochem Behav (1988) 0.87
Chronic nicotine administration in the drinking water affects the striatal dopamine in mice. Pharmacol Biochem Behav (2000) 0.87
Selective neurotoxic effects of nicotine on axons in fasciculus retroflexus further support evidence that this a weak link in brain across multiple drugs of abuse. Neuropharmacology (2000) 0.85
Differential regulation of nicotinic acetylcholine receptors in PC12 cells by nicotine and nerve growth factor. Mol Pharmacol (2003) 0.84
alpha-Bungarotoxin binding sites in rat hippocampal and cortical cultures: initial characterisation, colocalisation with alpha 7 subunits and up-regulation by chronic nicotine treatment. Brain Res (1995) 0.82
Tolerance to nicotine following chronic treatment by injections: a potential role for corticosterone. Psychopharmacology (Berl) (1992) 0.81
Discriminative stimulus effects of nicotine and chronic tolerance. Pharmacol Biochem Behav (1997) 0.79
Mecamylamine prevents tolerance but enhances whole brain [3H]epibatidine binding in response to repeated nicotine administration in rats. Psychopharmacology (Berl) (2000) 0.79
Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science (2004) 5.94
Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron (2002) 5.71
Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol (2004) 4.58
Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci (2002) 4.01
Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature (2011) 3.77
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron (2006) 3.37
Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) (2009) 2.76
In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron (2008) 2.69
Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum Mol Genet (2004) 2.61
Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci (2007) 2.37
The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry (2007) 2.19
The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol (2007) 2.03
The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. Mol Pharmacol (2003) 2.00
A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron (2002) 1.97
Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Mol Pharmacol (2007) 1.86
Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. Mol Pharmacol (2004) 1.84
Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B Neuropsychiatr Genet (2007) 1.82
Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron (2008) 1.80
Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release. J Neurosci (2009) 1.76
The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J Neurosci (2003) 1.73
Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med (2012) 1.72
Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res (2002) 1.68
Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. J Neurochem (2007) 1.57
The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco. Hum Mol Genet (2007) 1.57
Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet (2009) 1.54
Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res (2011) 1.49
Novel seizure phenotype and sleep disruptions in knock-in mice with hypersensitive alpha 4* nicotinic receptors. J Neurosci (2005) 1.42
Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci (2010) 1.41
Questioning standardization in science. Nat Methods (2009) 1.40
Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. Mol Pharmacol (2005) 1.38
Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. Hum Mol Genet (2006) 1.38
Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology (2010) 1.37
A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet (2009) 1.36
Rai1 duplication causes physical and behavioral phenotypes in a mouse model of dup(17)(p11.2p11.2). J Clin Invest (2006) 1.33
Phenotypic characterization of Bbs4 null mice reveals age-dependent penetrance and variable expressivity. Hum Genet (2006) 1.32
Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J Pharmacol Exp Ther (2002) 1.32
Induced chromosome deletions cause hypersociability and other features of Williams-Beuren syndrome in mice. EMBO Mol Med (2009) 1.30
A polymorphism in the alpha4 nicotinic receptor gene (Chrna4) modulates enhancement of nicotinic receptor function by ethanol. Alcohol Clin Exp Res (2003) 1.26
A polymorphism in the mouse neuronal alpha4 nicotinic receptor subunit results in an alteration in receptor function. Mol Pharmacol (2002) 1.26
Involvement of the alpha3 subunit in central nicotinic binding populations. J Neurosci (2002) 1.26
Modulation of nicotine but not ethanol preference by the mouse Chrna4 A529T polymorphism. Behav Neurosci (2005) 1.25
Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther (2002) 1.25
Behavioral characterization of mouse models for Smith-Magenis syndrome and dup(17)(p11.2p11.2). Hum Mol Genet (2004) 1.25
Subsets of acetylcholine-stimulated 86Rb+ efflux and [125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology (2004) 1.23
Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol (2003) 1.22
Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors. J Mol Neurosci (2009) 1.22
Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci (2008) 1.21
Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation. Mol Pharmacol (2002) 1.18
Striatal α5 nicotinic receptor subunit regulates dopamine transmission in dorsal striatum. J Neurosci (2012) 1.17
Acetylcholine-stimulated [3H]GABA release from mouse brain synaptosomes is modulated by alpha4beta2 and alpha4alpha5beta2 nicotinic receptor subtypes. Mol Pharmacol (2009) 1.17
Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology (2011) 1.17
Nicotine responses in hypersensitive and knockout alpha 4 mice account for tolerance to both hypothermia and locomotor suppression in wild-type mice. Physiol Genomics (2007) 1.16
Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. Nicotine Tob Res (2004) 1.16
Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. J Pharmacol Exp Ther (2011) 1.15
Knockout mouse model for Fxr2: a model for mental retardation. Hum Mol Genet (2002) 1.13
The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay. Neuropharmacology (2005) 1.12
Rai1 deficiency in mice causes learning impairment and motor dysfunction, whereas Rai1 heterozygous mice display minimal behavioral phenotypes. Hum Mol Genet (2007) 1.11
Gene targeting demonstrates that alpha4 nicotinic acetylcholine receptor subunits contribute to expression of diverse [3H]epibatidine binding sites and components of biphasic 86Rb+ efflux with high and low sensitivity to stimulation by acetylcholine. Neuropharmacology (2007) 1.06
Alpha 4 beta 2* nicotinic acetylcholine receptors modulate the effects of ethanol and nicotine on the acoustic startle response. Alcohol Clin Exp Res (2003) 1.05
Conditional expression in corticothalamic efferents reveals a developmental role for nicotinic acetylcholine receptors in modulation of passive avoidance behavior. J Neurosci (2003) 1.05
Deletion of the alpha7 nicotinic receptor subunit gene results in increased sensitivity to several behavioral effects produced by alcohol. Alcohol Clin Exp Res (2005) 1.05
Untranslated region-dependent exclusive expression of high-sensitivity subforms of alpha4beta2 and alpha3beta2 nicotinic acetylcholine receptors. Mol Pharmacol (2006) 1.04
The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handb Exp Pharmacol (2009) 1.04
Deletion of the alpha7, beta2, or beta4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine. Mol Pharmacol (2006) 1.04
Cortico-thalamic connectivity is vulnerable to nicotine exposure during early postnatal development through α4/β2/α5 nicotinic acetylcholine receptors. Neuropsychopharmacology (2010) 1.04
Immunolabeling demonstrates the interdependence of mouse brain alpha4 and beta2 nicotinic acetylcholine receptor subunit expression. J Comp Neurol (2006) 1.04
α6* nicotinic acetylcholine receptor expression and function in a visual salience circuit. J Neurosci (2012) 1.03
Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include α5 or α6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology (2012) 1.03
Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behav Pharmacol (2008) 1.03
Multiple autism-like behaviors in a novel transgenic mouse model. Behav Brain Res (2010) 1.02
Decreased anxiety-like behavior in beta3 nicotinic receptor subunit knockout mice. Pharmacol Biochem Behav (2007) 1.02
Impaired conditioned fear and enhanced long-term potentiation in Fmr2 knock-out mice. J Neurosci (2002) 1.02
An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. Biochem Pharmacol (2011) 1.02
Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res Mol Brain Res (2002) 1.01
Interaction of the nicotinic cholinergic system with ethanol withdrawal. J Pharmacol Exp Ther (2003) 1.01